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Tuberculosis is a leading cause of death worldwide. Resistance of Mycobacterium to antibiotics can make
treatments less effective in some cases. We tested selected oligopeptoids—previously reported as mimics of
natural host defense peptides—for activity against Mycobacterium tuberculosis and assessed their cytotoxicity.
A tetrameric, alkylated, cationic peptoid (1-C134mer) was most potent against M. tuberculosis and least cyto-
toxic, whereas an unalkylated analogue, peptoid 14mer, was inactive. Peptoid 1-C134mer thus merits further
study as a potential antituberculosis drug.
Mycobacterium tuberculosis is a Gram-positive bacterium
that infects human macrophages, causing tuberculosis (TB).
Approximately one-third of the world’s population is infected
with M. tuberculosis, and more than 10 new cases of TB occur
every minute, accounting for 2 to 2.5 million deaths annually
worldwide (9, 15, 24).
The current treatment for drug-sensitive M. tuberculosis in-
fections requires long-term multiple antibiotic therapy for 6 to
12 months (10). Mycobacterium bovis bacille Calmette-Gue´rin
(BCG), a vaccine against M. tuberculosis that is widely used for
children, can fail to prevent pulmonary TB in adult populations
(18). Widespread noncompliance with the full therapeutic reg-
imen has led to the inevitable emergence of multidrug-resis-
tant (MDR) strains of M. tuberculosis (17). Rising resistance to
rifampin and isoniazid, which are the most commonly used
anti-TB drugs (14), is cause for concern and provided the
motivation for this study. In spite of constant efforts to control
TB, the disease remains a grave global problem that demands
the discovery of novel treatments.
Naturally occurring antimicrobial peptides (AMPs), also
known as host defense peptides, serve as the first line of im-
mune defense for most organisms and as the sole immune
effector for some organisms, including insects (29). Typically,
they are relatively short (40 amino acids long) and quite
cationic (3 to 6 at pH 7) and adopt amphipathic structures
that present discrete hydrophobic and hydrophilic regions
when they are associated with anionic interfaces (e.g., with
anionic micelles). Some natural AMPs have alkyl modifications
as well (22, 27). The antimicrobial activity of these natural
toxins, which are typically released from granules, is attributed
to their disruptive interactions with the bacterial membrane
(29) in a manner involving non-receptor-mediated, poorly un-
derstood biophysical mechanisms of action (4, 11, 29). Their
apparently nonspecific modes of killing have apparently made
it difficult for bacteria to acquire resistance to AMPs, in con-
trast to the rising resistance of bacteria to small-molecule an-
tibiotics that bind to specific receptors, which are subject to
alteration via mutation and selection. Despite the efforts of
many groups, AMPs are not yet used widely as therapeutics for
a number of reasons, including their high cost, expectedly low
bioavailability (as a result of in vivo protease susceptibility),
and possible immunogenicity and/or systemic toxicity (12, 25).
Efforts to overcome these drawbacks have prompted the de-
sign and synthesis of various nonnatural mimics of AMPs,
which offer greater bioavailability and biostability, potentially
increasing pharmaceutical suitability (1, 2, 23, 25).
Oligo-N-substituted glycines (peptoids) are sequence-spe-
cific peptidomimetics that are based on a “biomimetic” peptide
backbone identical to that of natural proteins but have their
side chains attached to the amide nitrogen (21, 30). This struc-
tural difference makes them highly resistant to protease activity
(16, 19). In this study, we investigated the activity of six differ-
ent oligopeptoids as antimycobacterial compounds. Cationic
and amphipathic dodecamer peptoid 1, previously shown to
be active against a broad spectrum of bacteria and fungi, was
used as a positive control, whereas the cationic and aliphatic
dodecamer peptoid 1-Nssb, which is inactive against bacteria,
served as a negative control (6, 21). A previously designed
tetrameric, cationic, alkylated peptoid, 1-C134mer, also previ-
ously shown to be an active antibacterial compound (previ-
ously termed Ntridec-14mer) (5) was studied alongside unalky-
lated peptoid 1 analogues (1-11mer, 1-Pro9) and its own
unalkylated analogue, 14mer, to investigate the effects of N-ter-
minal alkylation and other molecular structural features on
antimycobacterial activity (Table 1). Peptoids were synthesized
by the standard solid-phase submonomer method (30) and
purified by reversed-phase high-performance liquid chroma-
tography on a C18 column with an acetonitrile-water gradient
(6, 21). The structures of the four different monomers used in
the six different sequence-specific peptoids are shown in Fig. 1,
while the actual sequences of the compounds are listed in
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Table 1. Gentamicin, an antibiotic commonly used against
BCG in culture, was included as a positive control (13, 28).
Antibacterial activity of peptoids against BCG. The MICs of
the six different peptoids against M. tuberculosis were assessed
using a luminescent, luciferase-expressing strain of BCG with
the use of bioluminescence as an indicator of cell viability (Fig.
2) (8). BCG was grown in Middlebrook 7H9 broth in the
presence of 5 g/ml of kanamycin, shaking, for 6 weeks at
37°C. In 6-ml surgical tubes, 2:1 serially diluted peptoid solu-
tions were incubated with BCG at 37°C for 1 h in a 2-ml total
volume and with a maximum concentration of 100 M. A
100-l volume of the solution was transferred to a black, clear-
bottom, 96-well plate, and then 2 l of a luciferin solution was
added. Bioluminescence was measured using an IVIS imaging
system (a Xenogen product from Caliper LifeSciences, Hop-
kinton, MA). Additional peptoid was added at 3, 6, and 23 h;
1 h after each addition, changes in the bioluminescent signal
intensity were measured. The MIC was defined as the concen-
tration at which no bioluminescence was observed after 24 h
and was reported as an average of three replicate trials. Error
bars represent the mean  standard deviation. Statistical dif-
ferences from the control (without added antimicrobial) were
determined by one-way analysis of variance (ANOVA) with
post hoc testing using the Tukey-Kramer method at the 24-h
time point. Differences were considered statistically significant
at a P value of 0.0001.
Without any added antibiotic compound, a steady increase
in bioluminescence was observed, giving an indication that
BCG was growing (Fig. 2). When antibiotic compounds were
added, decreases in bioluminescence over the first 4 h were
insignificant. For active compounds, however, a significant re-
duction in bioluminescence was seen after 24 h of incubation.
As shown in Fig. 2, 1-C134mer was the most active peptoid
(MIC  6.3 M) and was better than gentamicin (MIC  25
M) at inhibiting the growth of BCG. On the other hand, the
negative-control peptoids 1-Nssb and 14mer were inactive, even
at 100 M (Fig. 2). Peptoids 1, 1-11mer, and 1-Pro9 exhibited
MICs in the range of 12.5 to 25 M.
Antimicrobial activity of oligopeptoids against M. tuberculo-
sis: MABA. As another way to assess the antimycobacterial
activity of these compounds, we had the peptoids tested against
M. tuberculosis (H37Rv) using the microplate Alamar blue as-
say (MABA) by an NIH/NIAID-contracted laboratory (7). The
visual MIC was defined as the concentration at which the
peptoids prevented the change in color of the Alamar blue
solution.
The MICs of peptoids obtained by the testing lab with the
MABA were consistent with the MICs obtained with the bio-
luminescence assay (Table 1). Again, 1-C134mer demonstrated
the greatest tuberculocidal activity, whereas peptoid 1-Nssb
was ineffective. Peptoids 1, 1-11mer, and 1-Pro9 exhibited MICs
in the range of 14 to 15 M (Table 1).
Cytotoxicity of peptoids against macrophages. As a prelim-
inary assessment of the potential biocompatibility of peptoids
and their suitability for the treatment of TB infections, we
measured the cytotoxicity of peptoids against the Raw 264.7
and J774 mouse macrophage cell lines by a 3-(4,5-dimethylthi
azol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt, colorimetric viability assay (20). The
reported 50% lethal dose (LD50) represents the average value
that was obtained using data from six replicate trials. Means
and standard deviations are reported. Statistically significant
LD50 differences from the no-treatment control were deter-
mined by one-way ANOVA with post hoc testing using the
Tukey-Kramer method. Differences were considered statisti-
cally significant at a P value of 0.0001.
TABLE 1. Sequences and activities of six different peptoids and gentamicin against BCG and M. tuberculosis bacteriaa
Name Sequence (amino to carboxyamide)
MIC (M)
BCGb M. tuberculosis H37Rvc
Peptoid 1 H-(NLys-Nspe-Nspe)4-NH2 12.5–25 14.1
1-C134mer H-Ntridec-NLys-Nspe-Nspe-NLys-NH2 6.3 6.6
14mer H-NLys-Nspe-Nspe-NLys-NH2 100 ND
d
1-Pro9 H-(NLys-Nspe-Nspe)2-NLys-Nspe-L-Pro-NLys-Nspe-Nspe-NH2 12.5–25 14.5
1-11mer H-(NLys-Nspe-Nspe)3-NLys-Nspe-NH2 12.5–25 14.46
1-Nssb H-(NLys-Nssb-Nssb)4-NH2 100 100
Gentamicin 25 ND
a The MIC is the concentration at which no bioluminescence or lack of color change was observed in the two different assays used. MICs are represented as the
average of three replicate trials. The statistical analysis is shown in Fig. 1.
b Determined by luciferase assay.
c Determined by fluorescence assay.
d ND, not determined.
FIG. 1. Peptoid submonomer chemical structures.
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FIG. 2. BCG bioluminescence (in a luciferase-expressing Mycobacterium strain) at different concentrations of peptoid 1 (A), 1-C134mer (B),
1-11mer (C), 1-Pro9 (D), 1-Nssb (E), and gentamicin (F). Compounds were added at 0, 3, 6, and 23 h; bioluminescence was measured after 1 h of
dosing at 37°C. Peptoid 14mer was completely ineffective at reducing bioluminescence in this testing protocol (data not shown). The error bars
represent standard deviations. The differences were considered statistically significant (P  0.0001) with respect to a blank (no antimicrobial) at
24 h. p/s, photons/second.
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The LD50 (the dose that killed 50% of the cells) of one of
the peptoids (dodecamer 1) against macrophages was quite
close to its MIC; however, other peptoids were substantially
less toxic to macrophages at their MICs (Fig. 3). Peptoid
1-C134mer had an LD50 of 100 M, hence, its LD50 is 15 to
20 times higher than its MIC, which is 6.3 M. Peptoids
1-11mer and 1-Pro9 had 2- to 4-fold higher LD50 values (50
M) than their MICs (12.5 to 25 M). As mentioned above,
peptoid 1 has a very narrow biocompatibility window, with an
MIC of 12.5 to 25 M and an LD50 of 20 M. The inactive
negative-control peptoids—compounds 1-Nssb and 14mer—
were also nontoxic.
Three of the six peptoids investigated in this study showed
interesting tuberculocidal activity, and all three were equally
active against BCG and M. tuberculosis (Table 1). These three
different oligopeptoids (1-11mer, 1-Pro9, and 1-C134mer) may
also have useful therapeutic windows, judging by their cytotox-
icity in culture, with LD50/MIC ratios ranging from 2 to 20
(Fig. 3). These data indicate that they should be further inves-
tigated as potential anti-TB drugs.
Peptoid 1-C134mer is four residues long and cationic, with a
13-carbon aliphatic tail on its N terminus. The hydrophobic tail
of peptoid 1-C134mer gives it a substantial surfactant charac-
ter—as a monomer—and would be expected to interact
strongly, and disruptively, with the waxy, hydrophobic, lipid-
rich outer layer of Mycobacterium, enabling better peptoid
penetration of the bacterium, in a manner not seen in the case
of unalkylated peptoid 14mer. In general, cationic surfactants
are toxic to mammalian cells, as well as to bacteria, but this
case, the strong self-association of this oligopeptoid enforced
by its C13 tail must protect macrophages, which, unlike bacte-
ria, are not substantially anionic (or hydrophobic, in the case of
M. tuberculosis) on their outer membranes. Micellization of
1-C134mer at its MIC would be fully expected to increase its
anti-M. tuberculosis potency, since the labile micelles, after
binding to the anionic/hydrophobic bacterial membrane, would
dissociate, creating a high local concentration at the cell sur-
face (26). The cell membrane of Mycobacterium differs greatly
from that of typical Gram-positive and Gram-negative bacte-
ria. The outer layer of Mycobacterium is comprised of lipid-
rich, hydrophobic layers of mycolic acid, and this aliphatic,
hydrophobic wax barrier reduces the permeability of M. tuber-
culosis to the typical anti-TB drugs (3, 14). The inefficient
penetration of the drugs and/or the entrapment of drugs by the
waxy envelope layer are, in part, the reasons for the higher
resistance of Mycobacterium to antibiotics (18). The very slow
metabolism of Mycobacterium also has a tendency to render
most conventional drugs less effective because the latter com-
pounds often work by impairing particular steps in the cell’s
metabolic cycle.
This is the first study demonstrating the efficacy of cationic,
biomimetic peptoids against the particularly troublesome class
of infectious bacteria that lead to TB. We were excited to find
that certain peptoids show appreciable activity against both
BCG and M. tuberculosis while also being nontoxic or only
slightly toxic to macrophages at their MICs. The cationic,
amphipathic—in fact, surfactant-like—compound peptoid
1-C134mer was the most active and least cytotoxic. Presum-
ably, its ability to form stable micelles is important for its
selectivity. Since antimicrobial peptoids kill bacteria by a
nonspecific biophysical mechanism with the potential to cir-
cumvent bacterial resistance, they may have significant phar-
maceutical potential as a new class of tuberculocidal drugs
against MDR strains of M. tuberculosis.
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